Movement Alert｜CSPC PHARMA Rises 3.57% in Regular Trading, AstraZeneca siRNA Collaboration $30 Million Upfront Payment Received

Market Focus08-13 09:41

On August 13, CSPC PHARMA rose 3.57% in regular trading, trading at HK$8.95/share, with turnover of HK$102 million.

The movement was primarily driven by the company's announcement on August 12 that it has received a $30 million upfront payment from AstraZeneca under their siRNA drug collaboration, option, and license agreement signed in July. The partnership focuses on leveraging CSPC's proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to co-develop novel small nucleic acid drug candidates. This payment marks the formal commencement of the funding phase of the strategic collaboration.

The $30 million receipt follows a $10 million milestone payment received on August 5 under a separate strategic R&D collaboration, along with a joint venture agreement to build a next-generation biologics manufacturing facility in Shijiazhuang (CSPC 51%, AstraZeneca 49%). CSPC is scheduled to report interim results on August 20, with market consensus expecting H1 net profit growth exceeding 131%. Citi maintains a Buy rating with a target price of HK$11.5.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180086875?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180086875","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC PHARMA Rises 3.57% in Regular Trading, AstraZeneca siRNA Collaboration $30 Million Upfront Payment Received","media":"Market Focus","content":"<p><p>On August 13, CSPC PHARMA rose 3.57% in regular trading, trading at HK$8.95/share, with turnover of HK$102 million.</p><p>The movement was primarily driven by the company's announcement on August 12 that it has received a $30 million upfront payment from AstraZeneca under their siRNA drug collaboration, option, and license agreement signed in July. The partnership focuses on leveraging CSPC's proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to co-develop novel small nucleic acid drug candidates. This payment marks the formal commencement of the funding phase of the strategic collaboration.</p><p>The $30 million receipt follows a $10 million milestone payment received on August 5 under a separate strategic R&D collaboration, along with a joint venture agreement to build a next-generation biologics manufacturing facility in Shijiazhuang (CSPC 51%, AstraZeneca 49%). CSPC is scheduled to report interim results on August 20, with market consensus expecting H1 net profit growth exceeding 131%. Citi maintains a Buy rating with a target price of HK$11.5.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC PHARMA Rises 3.57% in Regular Trading, AstraZeneca siRNA Collaboration $30 Million Upfront Payment Received</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC PHARMA Rises 3.57% in Regular Trading, AstraZeneca siRNA Collaboration $30 Million Upfront Payment Received\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-13 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 13, CSPC PHARMA rose 3.57% in regular trading, trading at HK$8.95/share, with turnover of HK$102 million.</p><p>The movement was primarily driven by the company's announcement on August 12 that it has received a $30 million upfront payment from AstraZeneca under their siRNA drug collaboration, option, and license agreement signed in July. The partnership focuses on leveraging CSPC's proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to co-develop novel small nucleic acid drug candidates. This payment marks the formal commencement of the funding phase of the strategic collaboration.</p><p>The $30 million receipt follows a $10 million milestone payment received on August 5 under a separate strategic R&D collaboration, along with a joint venture agreement to build a next-generation biologics manufacturing facility in Shijiazhuang (CSPC 51%, AstraZeneca 49%). CSPC is scheduled to report interim results on August 20, with market consensus expecting H1 net profit growth exceeding 131%. Citi maintains a Buy rating with a target price of HK$11.5.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1180086875","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180086875","pubTimestamp":1786585311,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 13, CSPC PHARMA rose 3.57% in regular trading, trading at HK$8.95/share, with turnover of HK$102 million.The movement was primarily driven by the company's announcement on August 12 that it...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势提醒|石药集团常规交易上涨3.57%，阿斯利康siRNA合作收到3000万美元预付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On August 13, CSPC PHARMA rose 3.57% in regular trading, trading at HK$8.95/share, with turnover of HK$102 million.The movement was primarily driven by the company's announcement on August 12 that it has received a $30 million upfront payment from AstraZeneca under their siRNA drug collaboration, option, and license agreement signed in July. The partnership focuses on leveraging CSPC's proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to co-develop novel small nucleic acid drug candidates. This payment marks the formal commencement of the funding phase of the strategic collaboration.The $30 million receipt follows a $10 million milestone payment received on August 5 under a separate strategic R&D collaboration, along with a joint venture agreement to build a next-generation biologics manufacturing facility in Shijiazhuang (CSPC 51%, AstraZeneca 49%). CSPC is scheduled to report interim results on August 20, with market consensus expecting H1 net profit growth exceeding 131%. Citi maintains a Buy rating with a target price of HK$11.5.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180086875","isCrawlerRequest":true}